<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060007</url>
  </required_header>
  <id_info>
    <org_study_id>09-0696 / 201106272</org_study_id>
    <nct_id>NCT01060007</nct_id>
  </id_info>
  <brief_title>Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer</brief_title>
  <official_title>A Phase II Evaluation of Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if short course radiotherapy followed by chemotherapy can maintain morbidity at
      or below levels reported with concurrent 5FU, oxaliplatin, and radiotherapy, while
      maintaining response rates comparable to what would be expected with radiotherapy and
      concurrent chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our principal objectives in this trial will be to determine if short course radiotherapy
      followed by chemotherapy can maintain morbidity at or below levels reported with concurrent
      5FU (oral capecitabine if 5FU is unavailable), oxaliplatin, and radiotherapy, while
      maintaining response rates comparable to what would be expected with radiotherapy and
      concurrent chemotherapy. If we can establish a T stage downstaging rate that is significantly
      better than 50% and if acute tolerance is acceptable, then we would consider this study as
      having provided sufficient pilot data to support including this approach as an arm in a
      multi-institution phase III trial. The long-term goal is improved overall control of disease
      by delivering better chemotherapy earlier.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of T Stage Downstaging</measure>
    <time_frame>Mean number of weeks before surgery 17.3 (SD +/- 2.9 weeks)</time_frame>
    <description>T stage downstaging is defined as clinical pretreatment American Joint Committee on Cancer T stage (cT) being greater than pathologic T stage at surgery (ypT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preoperative Gastrointestinal Morbidity</measure>
    <time_frame>Mean number of weeks before surgery 17.3 (SD +/- 2.9 weeks)</time_frame>
    <description>As measured by participants who experience grade 3 or higher gastrointestinal morbidity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Any Late Grade 3 or Higher Morbidity</measure>
    <time_frame>Preoperative (mean time from start of radiation to surgery 17.3 weeks (SD +/- 2.9 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Post Chemoradiotherapy Grade 3 or Higher Morbidity</measure>
    <time_frame>1 year (completion of all treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Control</measure>
    <time_frame>30 months</time_frame>
    <description>Kaplan-Meier projections
Local control = control of primary tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Overall Control</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Locoregional Control</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Disease Relapse</measure>
    <time_frame>30 months</time_frame>
    <description>Kaplan-Meier projections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Quality of Anorectal Function</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Anorectal function was measured by the participant's response to the FACT-C questionnaire question &quot;I have control of my bowels&quot;. The answers ranged from 0=not at all to 4=very much.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant radiation followed by FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat ever other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation</intervention_name>
    <arm_group_label>Neoadjuvant radiation followed by FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Neoadjuvant radiation followed by FOLFOX</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>Neoadjuvant radiation followed by FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <arm_group_label>Neoadjuvant radiation followed by FOLFOX</arm_group_label>
    <other_name>Fluorouracil</other_name>
    <other_name>Efudex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Neoadjuvant radiation followed by FOLFOX</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven adenocarcinoma of the rectum

          -  Patient evaluated by surgeon and found to be a potential surgical candidate. Since the
             primary objectives are response to chemoradiation and acute toxicity, lesions which
             are initially unresectable are eligibleâ€”provided the surgeon feels that, if there is
             sufficient response, surgery could become feasible.

          -  Clinical evidence of T3 or T4 disease. This can be by imaging studies (see or by
             physical findings (tethering on palpation for T3 lesions or invasion of a neighboring
             organ for T4 lesions)

          -  Karnofsky Performance Status at &gt;60

          -  Laboratory criteria:

          -  Absolute neutrophil count &gt;= 1.5 K

          -  Platelets &gt;= 100 K

          -  Total Bilirubin &lt;= 2.0;

          -  SGOT and Alkaline Phosphatase &lt;= 2 x upper limit of normal

          -  Creatinine &lt; 2.0

          -  Hemoglobin &gt;= 8.0

          -  Informed consent signed

          -  Tumor measurable in at least one dimension. This may be, e.g. length and/or width
             measured endoscopically or on digital rectal examination, and maximum rectal wall
             thickness determined by imaging studies.

          -  Estimated longevity at least 12 months

          -  Patients with distant metastatic disease will be eligible if they satisfy all other
             conditions

        Exclusion Criteria:

          -  Pregnant women, children &lt; 18 years, or patients unable to give informed consent

          -  Patients with a past history of pelvic radiotherapy.

          -  Patients with any other malignancy within the past 5 years except: skin cancer or
             in-situ cervical cancer

          -  Patients with known allergy/intolerance to 5FU, Leucovorin, Oxaliplatin, Capecitabine

          -  Prior chemotherapy for colorectal cancer.

          -  Grade &gt;= 2 peripheral neuropathy

          -  Any condition which, in the opinion of the treating medical oncologist, renders the
             patient unfit for 5FU (oral capecitabine if 5FU is unavailable), Leucovorin,
             Oxaliplatin chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parag Parikh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <results_first_submitted>January 23, 2015</results_first_submitted>
  <results_first_submitted_qc>January 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2015</results_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened to participant enrollment on 11/10/2009 and closed to participant enrollment on 04/18/2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Neoadjuvant Radiation Followed by FOLFOX</title>
          <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat ever other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inevaluable for response at surgery</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neoadjuvant Radiation Followed by FOLFOX</title>
          <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat every other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical T stage</title>
          <description>T3: Tumor invades through the muscularis propria into pericolorectal tissues
T4a: Tumor penetrates to the surface of the visceral peritoneum
T4b: Tumor directly invades or is adherent to other organs or structures</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>cT3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cT4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical N stage</title>
          <description>N0: No regional lymph node metastasis.
N+: Metastases in 1 or greater lymph node(s)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>cN0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cN+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical M stage</title>
          <description>M0: No distant metastasis.
M1: Distant metastasis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>cM0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cM1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of T Stage Downstaging</title>
        <description>T stage downstaging is defined as clinical pretreatment American Joint Committee on Cancer T stage (cT) being greater than pathologic T stage at surgery (ypT).</description>
        <time_frame>Mean number of weeks before surgery 17.3 (SD +/- 2.9 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Radiation Followed by FOLFOX</title>
            <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat every other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of T Stage Downstaging</title>
          <description>T stage downstaging is defined as clinical pretreatment American Joint Committee on Cancer T stage (cT) being greater than pathologic T stage at surgery (ypT).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Preoperative Gastrointestinal Morbidity</title>
        <description>As measured by participants who experience grade 3 or higher gastrointestinal morbidity</description>
        <time_frame>Mean number of weeks before surgery 17.3 (SD +/- 2.9 weeks)</time_frame>
        <population>One patient was inevaluable for primary objectives because patient withdrew consent after completing radiation therapy, refused chemotherapy, and underwent a lesion resection 7 weeks after radiation therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Radiation Followed by FOLFOX</title>
            <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat every other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Preoperative Gastrointestinal Morbidity</title>
          <description>As measured by participants who experience grade 3 or higher gastrointestinal morbidity</description>
          <population>One patient was inevaluable for primary objectives because patient withdrew consent after completing radiation therapy, refused chemotherapy, and underwent a lesion resection 7 weeks after radiation therapy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Any Late Grade 3 or Higher Morbidity</title>
        <time_frame>Preoperative (mean time from start of radiation to surgery 17.3 weeks (SD +/- 2.9 weeks)</time_frame>
        <population>One patient was inevaluable for primary objectives because patient withdrew consent after completing radiation therapy, refused chemotherapy, and underwent a lesion resection 7 weeks after radiation therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Radiation Followed by FOLFOX</title>
            <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat every other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Any Late Grade 3 or Higher Morbidity</title>
          <population>One patient was inevaluable for primary objectives because patient withdrew consent after completing radiation therapy, refused chemotherapy, and underwent a lesion resection 7 weeks after radiation therapy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-hematologic toxicities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologic toxicities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Post Chemoradiotherapy Grade 3 or Higher Morbidity</title>
        <time_frame>1 year (completion of all treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Radiation Followed by FOLFOX</title>
            <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat every other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Post Chemoradiotherapy Grade 3 or Higher Morbidity</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Control</title>
        <description>Kaplan-Meier projections
Local control = control of primary tumor</description>
        <time_frame>30 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Radiation Followed by FOLFOX</title>
            <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat every other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Local Control</title>
          <description>Kaplan-Meier projections
Local control = control of primary tumor</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Overall Control</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Radiation Followed by FOLFOX</title>
            <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat every other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Overall Control</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Locoregional Control</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Radiation Followed by FOLFOX</title>
            <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat every other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Locoregional Control</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Disease Relapse</title>
        <description>Kaplan-Meier projections.</description>
        <time_frame>30 months</time_frame>
        <population>These include all cMO evaluable cases only.</population>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Radiation Followed by FOLFOX</title>
            <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat every other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Disease Relapse</title>
          <description>Kaplan-Meier projections.</description>
          <population>These include all cMO evaluable cases only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="76" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Quality of Anorectal Function</title>
        <description>Anorectal function was measured by the participant's response to the FACT-C questionnaire question &quot;I have control of my bowels&quot;. The answers ranged from 0=not at all to 4=very much.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Participants who had an ostomy were not included in this outcome measure. Participants who did not complete FACT-C questionnaire at a specific timepoint were not included in that timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-treatment</title>
          </group>
          <group group_id="O2">
            <title>Pre-surgery</title>
          </group>
          <group group_id="O3">
            <title>1 Year Post-treatment</title>
          </group>
        </group_list>
        <measure>
          <title>Determine Quality of Anorectal Function</title>
          <description>Anorectal function was measured by the participant's response to the FACT-C questionnaire question &quot;I have control of my bowels&quot;. The answers ranged from 0=not at all to 4=very much.</description>
          <population>Participants who had an ostomy were not included in this outcome measure. Participants who did not complete FACT-C questionnaire at a specific timepoint were not included in that timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 = not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 = a little bit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = quite a bit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 = very much</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events listed in the &quot;Other&quot; area have the word acute or late after the event name. Acute adverse events are followed from start of treatment until Day 90. Adverse events that occurred after Day 90 are referred to as late adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Neoadjuvant Radiation Followed by FOLFOX</title>
          <description>Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat ever other week for a total of 4 courses (this equals 6 weeks).
If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema (axilla)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Muscle spasm - bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Port-A-Cath Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin (acute)</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hemoglobin (late)</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain (acute)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain (acute)</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Abdominal pain (late)</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Anal incontinence (acute)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Anal incontinence (late)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Constipation (acute)</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Constipation (late)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dehydration (acute)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Diarrhea (acute)</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Diarrhea (late)</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fistula, GI (late)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Flatulence (acute)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>GI Leak (late)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia (late)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Rectum (acute)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI: melena (acute)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Ileus, GI (acute)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Ileus, GI (late)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Leak, GI (acute)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) (acute)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic) (acute)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic) (late)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea (acute)</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea (late)</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Perianal skin pain (acute)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rectal pain (acute)</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Small bowel NOS obstruction (late)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Taste alteration (acute)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Taste alteration (late)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urgency, GI (acute)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting (acute)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting (late)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Weight loss (acute)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Weight loss (late)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb (acute)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Edema: limb (late)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fatigue (acute)</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fatigue (late)</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fever (acute)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fever (late)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rigors/chills (acute)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rigors/chills (late)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Sweating (acute)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (late)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - UTI (acute)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils (acute)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1/2 neutrophils: abdomen (acute)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1/2 neutrophils: skin (late)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound complication, non-infectious (acute)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Wound complication, non-infectious (late)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (acute)</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (late)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>AST, SGOT (acute)</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>AST, SGOT (late)</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase (acute)</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase (late)</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Creatinine (acute)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Creatinine (late)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia (late)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>INR (acute)</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>INR (late)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Leukopenia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Leukopenia (late)</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Lymphopenia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Lymphopenia (late)</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (acute)</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (late)</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>PTT (acute)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Platelets (acute)</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Platelets (late)</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Anorexia (late)</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dehydration (late)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypercalcemia (late)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyperglycemia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyperglycemia (late)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyperkalemia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyperkalemia (late)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia (late)</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypocalcemia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypocalcemia (late)</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypoglycemia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypokalemia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypokalemia (late)</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia (late)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyponatremia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hyponatremia (late)</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain (acute)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Back pain (late)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Buttock pain (acute)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Jaw pain (acute)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Joint pain (acute)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Leg pain (late)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Muscle pain (acute)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Muscle weakness (late)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness (acute)</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dizziness (late)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Headache (acute)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Headache (late)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory (late)</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory (acute)</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Insomnia (late)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety (acute)</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression (acute)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Mood alteration-anxiety (late)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Mood alteration-depression (late)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain (acute)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pain: Dysuria (acute)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency (acute)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency (late)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urinary retention (acute)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urinary retention (late)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction (late)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough (acute)</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Cough (late)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspnea (acute)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspnea (late)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nose bleed (acute)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin (acute)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (acute)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pruritus/itching (acute)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rash/desquamation (acute)</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rash/desquamation (late)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rash: dermatitis associated with radiation (acute)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction (acute)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes (acute)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism (acute)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Parag Parikh, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-9703</phone>
      <email>pparikh@radonc.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

